World leading antibody scientist Dr Jane Osbourn awarded OBE in Queen’s Honours
Dr Jane Osbourn, Vice-President of Research and Development at AstraZeneca, has been made an Officer of the Order of the British Empire (OBE) in the Queen’s birthday honours list.
AstraZeneca announces StartUP Science Competition 2019
AstraZeneca is hosting its second StartUP Science Competition for life science entrepreneurs in the Cambridge area.
Lynparza approved in EU for the treatment of breast cancer
AstraZeneca and MSD Inc. have announced the European Commission has approved Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer.
AstraZeneca medicine approved in Europe for type-1 diabetes
AstraZeneca's Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes.
AstraZeneca presents advances in treatment options for ovarian and lung cancer patients
AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the ESMO 2018 Congress (European Society for Medical Oncology) in Munich, Germany, 19-23 October.
Attention life science entrepreneurs! Enter AstraZeneca's 'Start-Up Science' competition
Are you an early-stage Cambridge start-up focused on life sciences/healthcare? Time is running out to enter AstraZeneca's first ever Start-Up Science competition for life science entrepreneurs in the Cambridge area.
Cambridge life sciences cluster set to deliver additional £1billion to the UK economy by 2032
The Cambridge life sciences cluster has the potential to contribute an additional £1bn to the UK economy by 2032, according to independent research commissioned by AstraZeneca.
AstraZeneca and Lucy Cavendish College establish mentoring collaboration
AstraZeneca and Lucy Cavendish College, University of Cambridge, today announced that they have established a strategic collaboration to support their common goals of advancing women in science and business leadership, building on their existing relationship since the Company relocated its global HQ and R&D centre to Cambridge in 2016.
AstraZeneca aims to advance clinical practice in CV risk management with new data at ACC 2018
At the American College of Cardiology (ACC) 67th Annual Scientific Session & Expo 2018 in Orlando, Florida, this weekend, AstraZeneca will deliver industry-leading science and insights that augment the body of evidence on clinical approaches to tackling cardiovascular diseases.
MedImmune creates stand-alone company for early-stage inflammation and autoimmunity biologics
AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio. The new company will focus on developing medicines for severe autoimmune diseases by targeting the underlying causes of each disease.
It’s official: AstraZeneca and MedImmune ranked a top place for scientists to work by Science
AstraZeneca and MedImmune, its global biologics research and development arm, have been voted one of the top science employers worldwide, in the prestigious Science 2017 Top Employers Survey.
High tech collaboration reveals the dynamic structure of ATM
An advanced cryo-electron microscope allows AstraZeneca and Laboratory for Molecular Biology (LMB) scientists in Cambridge to uncover ground-breaking insights into a prime therapeutic target in cancer.
AstraZeneca and Pieris Pharmaceuticals collaborate on treatments for respiratory diseases
AstraZeneca has announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals, Inc. to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of…
AstraZeneca's bladder cancer drug gets FDA approval
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab).
Tagrisso receives full approval in the EU
AstraZeneca today announced that the European Commission (EC) has granted full marketing authorisation for Tagrisso (osimertinib) 40mg and 80mg once-daily tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
AstraZeneca's key milestone: ‘topping out’ of new global R&D centre and HQ in Cambridge UK
Latest milestone since AstraZeneca moved its global HQ and strategic science hub to Cambridge, UK, where the company already has 2,000 employees
Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer
AstraZeneca’s breast cancer treatment, Lynparza (olaparib), provided a statistically-significant improvement in progression-free survival compared to chemotherapy in the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer.
AstraZeneca and Lilly to develop treatment for Alzheimer’s disease
AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD). This agreement builds on the existing collaboration related to AZD3293, a BACE inhibitor in two pivotal Phase III trials.
Repositive and AstraZeneca announce members of PDX consortium
Repositive, a software company developing novel tools to improve discovery and access to human genomic research data, and AstraZeneca have announced the inaugural members of the PDX Consortium, which was set up to develop a collaborative, pre-competitive resource, to provide streamlined discovery and access to molecular data from Patient Derived Xenografts (PDXs) for use within oncology research.
AstraZeneca takes latest scientific advances in oncology to major US And European congresses
AstraZeneca and its global biologics research and development arm, MedImmune, will continue the oncology momentum built during 2016 with a strong end-of-year presence at three major congresses.
AstraZeneca climbs eight positions in Access to Medicine Index
The highest climber in the 2016 Index, AstraZeneca is now ranked seventh overall in providing access to medicine.
AstraZeneca purchases US facility to support biologics manufacturing capabilities
AstraZeneca announced that it has purchased a biologics manufacturing facility in Longmont, Colorado, USA, from Amgen Inc. This facility will be used to support AstraZeneca’s existing operations at its nearby Boulder site also purchased from Amgen in September of 2015.
Can ‘drag and drop’ cancer simulation speed up drug discovery?
Drug discovery scientists at AstraZeneca are working with Cambridge neighbours at Microsoft Research to develop new ‘drag and drop’ computer modelling of key signalling pathways in cancer cells, which may dramatically reduce the need for ‘wet’ lab experiments to bring truly personalised treatment to patients.
Trials show positive results in severe asthma for AstraZeneca's biologic medicine
AstraZeneca’s first biologic respiratory medicine met primary and key secondary endpoints in pivotal trials for severe asthma.
AstraZeneca completes commercialisation agreement with Aspen for anaesthetics portfolio
AstraZeneca announced that it has completed* the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US.